Astellas Seeks Advice On How To Leverage Prosidion Acquisition
This article was originally published in PharmAsia News
Executive Summary
Astellas is seeking outside help on what to do with its Prosidion biopharmaceutical subsidiary, which it bought from OSI Pharmaceuticals last June